A clinical trial update dated August 19, 2026 reports the status of a study registered as NCT04423211. The trial is titled "Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging." It is listed as a Phase 3 study and its current status is recruiting.
Triptorelin, an approved compound, is associated with this trial record. The study focuses on prostate cancer that has returned after surgery, using apalutamide together with targeted radiation guided by PET imaging.
No results have been posted for this trial as of the date of this update. The status reflects only that recruitment is ongoing at this phase of the study. No efficacy or safety outcomes are included in this update, and none should be inferred from the recruiting status alone.
Readers seeking further details can consult the official trial registry listing at the provided identifier for eligibility criteria, study design, and locations. For background on triptorelin itself, including its approved uses and general profile, see the compound overview.